生物医药全链条集成创新迎“江苏方案”

Core Viewpoint - The "Development Plan for the Open Innovation of the Biopharmaceutical Industry Chain in China (Jiangsu) Free Trade Zone" aims to enhance the biopharmaceutical industry's R&D innovation capabilities and improve service levels by implementing 18 key tasks across seven areas, with a target for significant growth by 2030 [1][2]. Group 1: Key Objectives and Tasks - The plan targets rapid growth in the biopharmaceutical industry scale in Jiangsu by 2030, with a focus on optimizing the innovation ecosystem and modernizing the industry chain [1]. - It aims to establish distinctive industrial clusters in key areas such as macromolecular biopharmaceuticals, cell and gene therapy, and innovative medical devices [1]. - The plan emphasizes the importance of the free trade zone as a comprehensive experimental platform for reform and innovation in the biopharmaceutical sector [1]. Group 2: R&D Innovation - The plan includes measures to enhance R&D innovation, focusing on advanced treatment methods like immunotherapy, stem cell therapy, and in vitro diagnostic reagents [2]. - It proposes the application of big data and artificial intelligence in drug target screening, molecular design, and medical device manufacturing [2]. - Support for clinical research in immunotherapy, stem cell therapy, and gene therapy is encouraged, along with participation in the formulation of national and industry standards [2]. Group 3: Production and Distribution - The plan suggests exploring pilot projects for segmented production of chemical raw materials and biological products [2]. - It supports regulatory reforms for the import and export of experimental animals and expands the pilot scope of the "white list" system for R&D materials [2]. Group 4: Financial Support and Data Management - The plan outlines five key tasks related to enhancing financial support for the biopharmaceutical industry, including facilitating financing for innovative companies through various stock exchanges and bond issuance [4]. - It encourages the establishment of investment sub-funds and supports the issuance of real estate investment trusts (REITs) for qualifying biopharmaceutical projects [4]. - The plan addresses cross-border data flow concerns by proposing a negative list for data export in the biopharmaceutical sector and establishing a public service platform for data security [4].